Since 1 November 2025, new reimbursement conditions apply in Belgium to complex reconstructions of large bone defects. This is particularly relevant for patients with bone cancer who, after the removal of a tumour, need a large part of a bone replaced with a megaprosthesis.

This change is part of a broader trend: complex and specialised care is increasingly concentrated in centres with specific expertise.

What is a megaprosthesis?

A megaprosthesis is a large prosthesis used to repair an extensive bone defect. In cancer, it may be needed when a large part of a bone has to be removed.

Megaprostheses are used, among other things, in:

  • bone cancer, such as osteosarcoma;
  • a soft tissue sarcoma that invades the bone;
  • complex reconstructions following tumour surgery;

But this also applies to large bone defects following a complex fracture around a joint prosthesis, or to situations where a prosthesis has to be removed, for example due to a serious bacterial infection.

 

What changed from 1 November 2025 onwards?

From 1 November 2025, the RIZIV has made reimbursement for reconstructions of large bone defects subject to specific conditions.

Within the regulations, a separate framework applies to centres for the reconstruction of large bone defects. Conditions also apply to the physician involved, the patient and the implant used. For example, the physician must demonstrate proven expertise in this type of reconstruction.

This means that in practice, care is heavily concentrated in a limited number of specialised centres, mainly within university hospitals.

Why is this care concentrated?

A megaprosthesis reconstruction is technically complex. The procedure requires specialised surgical knowledge and experience. In patients with sarcoma, good collaboration between different disciplines is also needed, both for treating the tumour and for the reconstruction and follow-up.

By concentrating this complex care, specialised teams can further build up their experience and expertise.

For patients, this means that they are increasingly treated for this type of procedure by a team with extensive experience in complex bone reconstructions.

What does this mean for patients?

For those who need a megaprosthesis, it is important to know that it is not only the operation itself that is complex. Preparation, the choice of implant, rehabilitation and follow-up also require specialised knowledge.

The new RIZIV/INAMI regulation links reimbursement for this care to clear conditions. The RIZIV/INAMI also publishes a list of hospitals and specialist physicians that fall within this official framework.

For patients with a rare condition such as sarcoma, this is an important development: complex bone reconstructions are increasingly being organised around specialised expertise and experience.